文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

直肠癌盆腔复发术后碳离子放疗后腰骶丛神经病前瞻观察子分析

Lumbosacral Plexopathy After Carbon-ion Radiation Therapy for Postoperative Pelvic Recurrence of Rectal Cancer: Subanalysis of a Prospective Observational Study (GUNMA 0801).
PubMed 文献 · Adv Radiat Oncol · 2025-02-07

本研究基于GUNMA 0801前瞻观察研究,分析20例直肠癌术后盆腔复发接受碳离子放疗(总剂量73.6 Gy(RBE)/16次)的患者,评估腰骶丛神经病(RILSP)发生率及剂量学参数。中位随访24个月,40条腰骶丛中全部RILSP和2级RILSP发生率分别为22.5%(9/40)和10%(4/40),未观察到≥3级毒性。RILSP患者各剂量区间受照体积均显著高于无RILSP患者(P<.001),D2 cm3和V50 Gy(RBE)的预测界值分别为73.82 Gy(RBE)和33.2%。

要点

  • 40条腰骶丛中全部RILSP发生率为22.5%(9/40),2级RILSP为10%(4/40),无≥3级毒性。
  • RILSP患者各剂量区间受照腰骶丛体积均显著高于无RILSP患者(P<.001)。
  • D2 cm3≥73.82 Gy(RBE)和V50 Gy(RBE)=33.2%为预测RILSP的界值。

核心结论

  • D2 cm3≥73.82 Gy(RBE)和V50 Gy(RBE)=33.2%为预测碳离子放疗后腰骶丛神经病的界值。

研究设计与样本

  • GUNMA 0801前瞻观察研究子分析,纳入28例患者,分析其中20例碳离子放疗前无腰骶丛神经病者,总剂量73.6 Gy(RBE)/16次。

主要发现

  • 中位随访24个月,20例患者40条腰骶丛中全部RILSP(1级和2级)发生率为22.5%(9/40),2级RILSP为10%(4/40),未观察到≥3级毒性。
  • RILSP患者受照腰骶丛体积在各剂量区间均显著高于无RILSP患者(Dmax、D0.5 cm3-D2 cm3、V20 Gy(RBE)-V70 Gy(RBE)的P<.001)。
  • 受试者工作特征分析认为D2 cm3和V50 Gy(RBE)有用,RILSP的界值分别为73.82 Gy(RBE)和33.2%。

关键数值与推荐

  • RILSP预测界值:D2 cm3≥73.82 Gy(RBE),V50 Gy(RBE)=33.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Data are lacking on the risk factors for radiation-induced lumbosacral plexopathy (RILSP) after carbon-ion radiation therapy (CIRT) for pelvic tumors, such as postoperative recurrence of rectal cancer. We investigated the incidence of RILSP and the associated dosimetric parameters using data from a prospective study of CIRT for postoperative pelvic recurrence of rectal cancer (GUNMA 0801). METHODS AND MATERIALS: The GUNMA 0801 study included 28 patients, of which we analyzed 20 without lumbosacral plexopathy prior to CIRT. The total dose of CIRT was 73.6 Gy (relative biological effectiveness [RBE]) in 16 fractions. The incidence of RILSP and parameters of the dose-volume histogram were evaluated for the lumbosacral plexuses. RILSP was graded according to the Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Median follow-up was 24 months. The incidence of all RILSP (grades 1 and 2) and grade 2 RILSP was 22.5% (9/40) and 10% (4/40) of 40 lumbosacral plexuses in 20 patients, respectively, and no grade ≥ 3 toxicity was observed. Throughout the dose range, the volumes of the irradiated lumbosacral plexuses were significantly higher in patients with RILSP than in patients without RILSP (P < .001 for Dmax, D0.5 cm3 - D2 cm3, V20 Gy(RBE) - V70 Gy(RBE)). D2 cm3 and V50 Gy(RBE) were considered useful for receiver operating characteristic analysis. Cutoff values for RILSP were 73.82 Gy(RBE) and 33.2% for D2 cm3 and V50 Gy(RBE), respectively. CONCLUSIONS: We demonstrated the incidence and predictive dosimetric parameters for RILSP after CIRT and showed that D2 cm3 ≥ 73.82 Gy(RBE) and V50 Gy(RBE) = 33.2% are cutoff values for predicting RILSP. These results would improve treatment plans using CIRT for patients with pelvic recurrences of rectal cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kumazawa T, Shiba S, Miyasaka Y, et al. Lumbosacral Plexopathy After Carbon-ion Radiation Therapy for Postoperative Pelvic Recurrence of Rectal Cancer: Subanalysis of a Prospective Observational Study (GUNMA 0801). Adv Radiat Oncol. 2025. PMID: 40007614. doi:10.1016/j.adro.2024.101711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。